Independent Financial Group LLC Purchases Shares of 1,012 Regeneron Pharmaceuticals, Inc. $REGN

Independent Financial Group LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,012 shares of the biopharmaceutical company’s stock, valued at approximately $782,000.

A number of other large investors have also made changes to their positions in the stock. Prosperity Consulting Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 5.9% in the first quarter. Prosperity Consulting Group LLC now owns 360 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 20 shares during the period. Aware Super Pty Ltd as trustee of Aware Super bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $2,938,000. Wealthfront Advisers LLC grew its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the 1st quarter. Wealthfront Advisers LLC now owns 8,344 shares of the biopharmaceutical company’s stock worth $6,447,000 after purchasing an additional 202 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.8% during the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 15 shares during the period. Finally, Sanctuary Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.2% in the first quarter. Sanctuary Advisors LLC now owns 40,631 shares of the biopharmaceutical company’s stock valued at $31,393,000 after purchasing an additional 1,649 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on REGN. Canaccord Genuity Group decreased their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Finally, JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $787.88.

Regeneron Pharmaceuticals Trading Up 0.5%

Shares of REGN stock opened at $675.19 on Wednesday. The company has a market capitalization of $71.38 billion, a P/E ratio of 16.45, a P/E/G ratio of 1.49 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $639.22 and a 200 day moving average price of $716.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned $8.22 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued analyst confidence in the company’s longer-term outlook.
• Neutral Sentiment: Regeneron said it completed a mid-stage study for REGN7544 in POTS, which could be relevant for its pipeline, but the market impact is unclear from the update alone.
• Negative Sentiment: Multiple law firms announced or reminded investors about a pending class action lawsuit against Regeneron related to disclosures around a Phase 3 melanoma study failure, reinforcing legal and reputational risk for the stock.
• Negative Sentiment: The lawsuit filings and deadline reminders suggest the company faces ongoing litigation risk and potential distraction as investors focus on trial disclosure concerns rather than near-term fundamentals.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.